top of page
News
Chat
Insights
Portfolios
Education
About
Plans/Pricing
API/MCP
New Era In Alzheimer's Treatments Brings Opportunities for Biopharma Investors
ALHEIMER’S BREAKTHROUGH
Jun 19, 2023
Is PRTA Worth It's EV of $2B?
$PRTA: Is it worth current EV of $1.B?
Apr 8, 2023
How does Lecanemab compare to other Alzheimer's assets?
Summary: Biogen and Eisai's asset Lecanemab has a PDUFA date set for Friday 1/6/23 Lecanemab targets and effectively reduces beta-amyloid...
Jan 4, 2023
How does Lecanemab compare to other Alzheimer's assets?
Summary:
Jan 4, 2023
Jump start your biotech due diligence
Get started →
Our platform helps you uncover your next biotech investment opportunity
bottom of page
